(Note: This is NOT an IPO. This is an uplisting to the NASDAQ of American Depositary Shares (ADS). The company’s  outstanding Ordinary Shares trade on the Australian Securities Exchange, or ASX, under the symbol “AHI”. This is a 1-million-unit offering on the NASDAQ, according to F-1/A filing dated Nov. 16, 2021: The 1 million units consist of  2 million American Depositary Shares (ADS) representing 16,000,000 Ordinary Shares and Warrants to Purchase 1,000,000 ADSs Representing 8,000,000 Ordinary Shares.)

We have developed and patented a proprietary measurement/dimensioning technology that enables a User to check, track, and accurately assess their body dimensions privately using only a smartphone. We refer to this physical measurement and analytics tool as “BodyScan.” We have global customers/partners (“Partners”) who utilize our technology through a Software Development Kits (“SDKs”). Our global Partners have substantial audiences that they address, and from those underlying audiences, individual User (“User(s)”) will sign up for, or be given access to, the Partners’ software programs/apps that embed our technology components. Our global Partners currently include companies within the following sectors: (i) mobile health (“mHealth”), Telehealth, and Wellness; (ii) Life and Health Insurance; (iii) Fitness; and (iv) Consumer and Apparel.

Our patented technology allows our Partners to supply to individual Users, via our automated technology, the ability to take a series of images of themselves using a smartphone, which delivers accurate and repeatable measurements across an individual’s entire body. These measurements allow the individual to understand his/her dimensions and the physical changes that they are undergoing through diet, exercise and lifestyle modification. Further, the images that we capture also provide the individuals with an understanding of their potential health risks related to certain chronic diseases (including obesity and diabetes) and using the global standards measurements set by the World Health Organization (“WHO”), and the International Diabetes Federation (“IDF”). Once the image capture sequence is completed, it supplies those measurements to the Partner’s application, whose contract with the User then determines the manner in which it analyzes/reports the data and/or the potential health risk to the User. We are working towards globalizing our technology in order to assist individuals, communities and populations live healthier lives.

We operate a business-to-business (“B2B”) model and revenue is generated on both a subscription basis as well as on demand-use basis. 

Note: Revenue and net loss figures are in U.S. dollars (converted from Australian dollars in the prospectus) for the 12 months that ended June 30, 2021.

(Note: Advanced Human Imaging, Ltd. priced its NASDAQ uplisting of ADS on Nov. 18, 2021, at $10.50 – slightly below the mid-point of its $10-to-$12 range – and priced 1 million units, the same number of units as in the prospectus, to raise  did not price its IPO on Nov. 11, 2021. With each unit representing 2 ADS, the IPO price per ADS is $5.25. The ADS started trading Friday, Nov. 19, 2021, on NASDAQ at $5.10, below the $5.25 IPO price, and then slipped to $4.31 by 12:36 p.m. EST.)